TY - JOUR
T1 - Insulin and other antidiabetic drugs and hepatocellular carcinoma risk
T2 - A nested case-control study based on Italian healthcare utilization databases
AU - Bosetti, Cristina
AU - Franchi, Matteo
AU - Nicotra, Federica
AU - Asciutto, Rosario
AU - Merlino, Luca
AU - La Vecchia, Carlo
AU - Corrao, Giovanni
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Purpose: Insulin and other antidiabetic drugs may modulate hepatocellular carcinoma (HCC) risk in diabetics. Methods: We have analyzed the role of various antidiabetic drugs on HCC in a nested case-control study using the healthcare utilization databases of the Lombardy Region in Italy. This included 190 diabetic subjects with a hospital discharge reporting a diagnosis of malignant HCC and 3772 diabetic control subjects matched to each case on sex, age, date at cohort entry, and duration of follow-up. Results: Increased risks of HCC were found for use of insulin (odds ratio [OR]=3.73, 95% confidence interval [CI] 2.52-5.51), sulfonylureas (OR=1.39, 95%CI 0.98-1.99), and repaglinide (OR=2.12, 95%CI 1.38-3.26), while a reduced risk was found for use of metformin (OR=0.57, 95%CI 0.41-0.79). The risk of HCC increased with increasing duration of insulin use (OR=2.52 for
AB - Purpose: Insulin and other antidiabetic drugs may modulate hepatocellular carcinoma (HCC) risk in diabetics. Methods: We have analyzed the role of various antidiabetic drugs on HCC in a nested case-control study using the healthcare utilization databases of the Lombardy Region in Italy. This included 190 diabetic subjects with a hospital discharge reporting a diagnosis of malignant HCC and 3772 diabetic control subjects matched to each case on sex, age, date at cohort entry, and duration of follow-up. Results: Increased risks of HCC were found for use of insulin (odds ratio [OR]=3.73, 95% confidence interval [CI] 2.52-5.51), sulfonylureas (OR=1.39, 95%CI 0.98-1.99), and repaglinide (OR=2.12, 95%CI 1.38-3.26), while a reduced risk was found for use of metformin (OR=0.57, 95%CI 0.41-0.79). The risk of HCC increased with increasing duration of insulin use (OR=2.52 for
KW - Antidiabetics
KW - Diabetes
KW - Hepatocellular carcinoma
KW - Insulin
KW - Metformin
KW - Pharmacoepidemiology
UR - http://www.scopus.com/inward/record.url?scp=84933670325&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84933670325&partnerID=8YFLogxK
U2 - 10.1002/pds.3801
DO - 10.1002/pds.3801
M3 - Article
C2 - 26013675
AN - SCOPUS:84933670325
VL - 24
SP - 771
EP - 778
JO - Pharmacoepidemiology and Drug Safety
JF - Pharmacoepidemiology and Drug Safety
SN - 1053-8569
IS - 7
ER -